Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial (vol 75, pg 1080, 2018)

被引：0
|
作者：
Stauffer, V. L.
Dodick, D. W.
Zhang, Q.
Carter, J. N.
Ailani, J.
Conley, R. R.
机构：
来源：
JAMA NEUROLOGY | 2019年 / 76卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：872 / 872
页数：1
相关论文
共 50 条
  • [1] Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial (vol 75, pg 1080, 2018)
    Stauffer, V. L.
    Dodick, D. W.
    Zhang, Q.
    Carter, J. N.
    Ailani, J.
    Conley, R. R.
    JAMA NEUROLOGY, 2018, 75 (09) : 1156 - 1156
  • [2] Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
    Stauffer, Virginia L.
    Dodick, David W.
    Zhang, Qi
    Carter, Jeffrey N.
    Ailani, Jessica
    Conley, Robert R.
    JAMA NEUROLOGY, 2018, 75 (09) : 1080 - 1088
  • [3] Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial (vol 75, pg 187, 2018)
    Skljarevski, V
    JAMA NEUROLOGY, 2018, 75 (02) : 260 - 260
  • [4] Phase 3 Study (EVOLVE-1) of Galcanezumab in Episodic Migraine
    Stauffer, V. L.
    Zhang, Q.
    Skljarevski, V
    Millen, B.
    Yang, J.
    Selzler, K. J.
    Conley, R.
    HEADACHE, 2017, 57 (08): : 1336 - 1336
  • [5] Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2) (vol 20, 75, 2019)
    Silberstein, Stephen D.
    Stauffer, Virginia L.
    Day, Katie A.
    Lipsius, Sarah
    Wilson, Maria-Carmen
    JOURNAL OF HEADACHE AND PAIN, 2019, 20 (01):
  • [6] Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
    Skljarevski, Vladimir
    Matharu, Manjit
    Millen, Brian A.
    Ossipov, Michael H.
    Kim, Byung-Kun
    Yang, Jyun Yan
    CEPHALALGIA, 2018, 38 (08) : 1442 - 1454
  • [7] Effect of galcanezumab in women with episodic migraine meeting criteria for menstrually related migraine: A post hoc analysis of EVOLVE-1 and EVOLVE-2
    Macgregor, E. Anne
    Okonkwo, Rose
    Detke, Holland C.
    Polavieja, Pepa
    Fernandes, Maria S.
    Pavlovic, Jelena M.
    HEADACHE, 2024, 64 (02): : 179 - 187
  • [8] Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
    Skljarevski, Vladimir
    Oakes, Tina M.
    Zhang, Qi
    Ferguson, Margaret B.
    Martinez, James
    Camporeale, Angelo
    Johnson, Kirk W.
    Shan, Qiuling
    Carter, Jeffrey
    Schacht, Aaron
    Goadsby, Peter J.
    Dodick, David W.
    JAMA NEUROLOGY, 2018, 75 (02) : 187 - 193
  • [9] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [10] Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase
    Skljarevski, Vladimir
    Stauffer, Virginia L.
    Zhang, Qi
    Detke, Holland C.
    Millen, Brian A.
    Yang, Jyun Yan
    Selzler, Katherine J.
    Conley, Robert
    Aurora, Sheena K.
    CEPHALALGIA, 2017, 37 : 339 - 340
12345